N-(2-氨基乙基)环己胺 | 5700-53-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(2-氨基乙基)环己胺
• 中文别名: N'-环己基乙烷-1,2-二胺
• 英文名称: N-cyclohexylethylenediamine
• 英文别名: N-Cyclohexylethylendiamin；N1-cyclohexylethane-1,2-diamine；N-Cyclohexyl-1,2-ethanediamine；N'-cyclohexylethane-1,2-diamine
• CAS: 5700-53-8
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: FCZQPWVILDWRBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)环己胺 在 盐酸 、 sodium hydroxide 作用下， 以 水 、 丙酮 、 苯 为溶剂， 反应 10.0h， 生成 1-<sulfonyl>-3-cyclohexyl-2-iminoimidazolidine dihydrochloride
  参考文献：
  名称：

  Sulfonyliminoimidazolidines. A new class of oral hypoglycemic agents. 1. 1-[[p-[2-(Acylamino)ethyl]phenyl]sulfonyl]-2-iminoimidazolidines

  摘要：

  A series of 1-[[p-[2-(acylamino)ethyl]phenyl]sulfonyl]-2-iminoimidazolidines has been synthesized. Compounds from this new class of oral hypoglycemic agents lower blood glucose in normal and in streptozotocin-diabetic rats. Potent analogues were obtained by modification of the acyl residue. 1-[[p-[2-(Crotonylamino)ethyl]phenyl]-sulfonyl]-3-cyclohexyl-2-iminoimidazolidine (44) turned out to be the most potent compound in the normal rat (20 times tolbutamide), and 1-[[p-[2-(5-methylisoxazole-3-carboxamido)ethyl]phenyl]sulfonyl]-3-cyclohexyl-2-imino-imidazolidine (30) displayed the highest potency in the diabetic rat (similar to phenformin).

  DOI：

  10.1021/jm00361a006
• 作为产物：
  描述：

  2-(Cyclohexylideneamino)ethanamine 在 三乙酰氧基硼氢化钠 作用下， 反应 24.0h， 生成 N-(2-氨基乙基)环己胺
  参考文献：
  名称：

  新型咪唑4-羧酸衍生物的合成及抗血小板活性

  摘要：

  合成了 1-Aryl烷基-5-苯基磺氨基-咪唑-4-羧酸酯及其带有额外仲氨基的羧酰胺，并鉴定为低微摩尔范围内的抗血小板药物（Born test，诱导胶原蛋白）。为了更准确地描述作用机制，还分别用 ADP、肾上腺素或 PAF 进行了 Born 测试。此外，研究了两种化合物的 COX-1 抑制活性。如果满足基本结构标准，即酰胺基团或酯、磺酰氨基残基、疏水部分和仲氨基官能团，轻微的结构修饰能够改变上述血小板受体之间的活性模式。因此，酯 5c 在 IC50 = 1 μM 和 COX-1 抑制 (IC50 = 0.4 μM) 下表现出 PAF 拮抗活性。甲酰胺 6c 显示出 ADP 拮抗特性 (IC50 = 2 µM)。化合物 6g 也是 PAF 拮抗剂 (IC50 = 4 μM) 和 COX-1 抑制剂 (IC50 = 1 μM)。衍生物 6i 显示出强烈的抗肾上腺素能 (IC50 = 0.15 μM)

  DOI：

  10.1002/ardp.200500150

文献信息

• 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS
  申请人：SCHOENAFINGER Karl

  公开号：US20070072866A1

  公开（公告）日：2007-03-29

  The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase —3β (GSK-3β) which is believed to cause the neurodegeneration that results in these diseases.

  本发明涉及激酶抑制剂化合物及其衍生物，以及包含它们的组合物，用于治疗诸如阿尔茨海默病、帕金森病、肥胖症、高血压等神经系统疾病。这些吡啶酮衍生物尤其抑制糖原合酶激酶-3β（GSK-3β）的代谢活性，据信这种活性导致了这些疾病的神经退行性变化。
• [EN] BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] BIS-PYRIDYLPYRIDONES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE DE MELANO-CONCENTRATION
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010141539A1

  公开（公告）日：2010-12-09

  The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1 ), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.

  这项发明提供了新型的双吡啶基吡啉酮，它们是黑素浓缩激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备方法，以及它们在治疗和治疗肥胖和糖尿病中的用途。
• Carbazole-Containing Sulfonamides as Cryptochrome Modulators
  申请人：Reset Therapeutics, Inc.

  公开号：US20130303524A1

  公开（公告）日：2013-11-14

  The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

  本文涉及含有咔唑基磺胺衍生物及其药用可接受盐或水合物的结构式I，其中变量R1、R2、R3、R4、R5、R6、R7、A、B、C、D、E、F、G、H、a和b分别描述。还提供了包含式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、肥胖症、代谢综合征、库欣综合征和青光眼。
• CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
  申请人：ReSet Therapeutics, Inc.

  公开号：US20150284362A1

  公开（公告）日：2015-10-08

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

  本文涉及含有咔唑基的酰胺、碳酸酯和脲衍生物，以及其结构式I中的药用可接受盐或水合物，其中变量R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a和b分别描述。还提供了含有式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、与糖尿病相关的并发症、库欣综合征、NASH、NAFLD、哮喘和COPD。
• Antibacterial water-soluble cutting fluids resistant to yeast-like fungi
  申请人：YUSHIRO CHEMICAL INDUSTRY CO. LTD.

  公开号：EP0388320A1

  公开（公告）日：1990-09-19

  A bactericide is added to conventional water-soluble cutting fluids to suppress deterioration by micro­organisms. Such fluids are however accompanied by the drawbacks that the bactericide has a narrow antibacterial spectrum and moreover its effects last a short time. It is the object of the present invention to offers water-­soluble cutting fluids which remain resistant to a wide variety of microorganisms for a long time. The present invention therefore offers water-soluble cutting fluids to which has been added a specific amine selected from amines known to date.

  将细菌杀灭剂添加到传统的水溶性切削液中，以抑制微生物的腐败。然而，这种液体伴随着细菌杀灭剂的缺点，即细菌杀灭剂的抗菌谱较窄，而且其效果持续时间较短。本发明的目的是提供一种长时间保持对各种微生物具有抗性的水溶性切削液。因此，本发明提供了一种水溶性切削液，其中添加了一种特定的胺，该胺是从迄今为止已知的胺中选择的。